Skip to main content

Table 2 iPSC-derived cellular agents for immunotherapy

From: Generation and clinical potential of functional T lymphocytes from gene-edited pluripotent stem cells

Organization Product Cell type Tumor type Characteristic Phase/ClinicalTrials.gov Identifier
National Cancer Institute (NCI) iPSC T T Gastrointestinal Cancers
Breast Cancer
Pancreatic Cancer
Melanoma
Lung Cancer
1) Generation of an iPSC-derived thymic organoid
2) Cancer antigen-specific T-cells
Preclinical studies/NCT03407040
Fate Therapeutics FT819 T B-cell Malignancies 1) CAR19 1XX placed under the control of endogenous TCR activity;
2) TCR KO
Phase 1/NCT04629729
FT500 NK Advanced solid tumors Phase 1/NCT03841110
FT596 NK r/rB Lymphoma
B-CLL
1) CD19 CAR
2) High-affinity 158 V, non-cleavable CD16 (hnCD16) Fc receptor
3) IL-15 receptor fusion (IL-15RF)
Phase 1/NCT04245722
FT516 NK r/rAML
r/rB-cell lymphoma
Advanced solid tumors
hnCD16 Fc receptor Phase 1 /NCT04551885/ NCT04023071
FT536 NK 1) MICA/B CAR
2) IL15RF
3) CD38 KO
Preclinical studies/-
FT538 NK Advanced hematologic malignancies 1) hnCD16 Fc receptor
2) IL15RF
3) CD38 KO
Phase 1/NCT04614636
FT573 NK Solid/hematologic malignancies 1) B7H3 CAR
2) hnCD16 Fc receptor
3) IL15RF
4) CD38 KO
Preclinical studies/-
FT576, NK MM 1) BCMA CAR
2) hnCD16 Fc receptor
3) IL15RF
4) CD38 KO
Preclinical studies/-
Allogene Therapeutics + Notch Therapeutics iPSC-AlloCAR T/NK NHL
Leukemia
MM
Generating from synthetic Engineered Thymic Niche (ETN) platform Preclinical studies/-
Century Therapeutics –NTY-101 NK r/r B-cell lymphoma 1) CD19 CAR
2) expressing soluble IL-15
3) EGFR safety switch
Preclinical studies/-
CNTY-103 NK Recurrent glioblastoma CD133 + EGFR CAR Preclinical studies/-
CNTY-102 T/NK r/rB-cell lymphoma
Other B-cell malignancies
CD19 + CD79b CAR Preclinical studies/-
CNTY-104 T/NK AML Multi-specific Preclinical studies/-
CiRA + Takeda iCART T Preclinical studies/-
Cartherics NK ovarian cancer 1) TAG72 CAR
2) Delete immune suppression gene
3) Multiple anti-cancer functionality
Preclinical studies/-
T CAR construct Preclinical studies/-
Shoreline Biosciences NK Preclinical studies/-
Mac Preclinical studies/-
CellOrigin NK Hematological malignancies Preclinical studies/-
iPSC-CAR-Mac01/02/03/04 Mac Solid Tumor Preclinical studies/-
iPSC-CAR-NK01 NK Solid tumor Preclinical studies/-
HebeCell NK 1) Generating from 3D bioreactors
2) CAR construction
Preclinical studies/-
Neukio Biotherapeutics NK CAR construction Preclinical studies/-
nuwacell T/NK CAR construction Preclinical studies/-
Biotheus + iCAMUN iPSC-CAB-NK NK Solid tumor Preclinical studies/-
PersonGen iPS-CAR-NK NK CAR construction Preclinical studies/-
  1. NK natural killer, MM multiple myeloma, AML acute myeloid leukemia